Track topics on Twitter Track topics that are important to you
Sociable Pharma's Treatment Landscape' contains evaluations of ongoing development activities within the Renal Anemia market, analysis of current potential future product positioning, and forecast approval dates by quarter for candidates in Phase II development, or higher
Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma's view of the disease landscape
Landscape Updates: Order of Entry' analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product's lifecycle management initiatives; Market Entry' Direction of Travel' positioning analysis for pipeline currently approved therapies
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drugspecific events milestones until YE 2019
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drugspecific events milestones until YE 2019
Roxadustat is still expected to be first HIFPHI to launch in the EU US markets, which may contribute to its superior uptake vs. other HIFPHI candidates, given the current lack of clinical differentiation between candidates of this class
In addition to progressing vadadustat's Phase III trials in Japan, Mitsubishi Tanabe also appears focused on understanding the impact of a commonly used renal anemia strategy, iron supplementation, on the pharmacokinetics of vadadustat
Daprodustat's Phase III data appears to strengthen the asset's longterm safety and efficacy profile, with daprodustat on track to become the second or third HIFPHI approved in Japan for DDCKD.
The briefing is based on Sociable Pharma's analysis of clinical trial data from company announcements press releases, earnings calls and clinical trial databases clinicaltrials.gov
Sociable Pharma applies disease drug specific assumptions in order to forecast US EU approvals for drugs in Phase II development, or higher these are outlined in the report Appendix
Forecasts are presented in pipeline forecast figures detailed tables
Market Entry' Direction of Travel' positioning analysis for pipeline currently approved therapies is also provided.
Reasons to buy
Provides details on forecast US EU approvals for pipeline drugs in Phase II development or higher
Includes potential positioning strategies that companies may adopt for their novel assets once they are approved launched in the market
Reviews ongoing lifecycle management strategies for existing players in the market
A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.NEXT ARTICLE
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells. In vertebrates, it is composed of blo...
Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...